Trastornos de ansiedad - Parte 2 -
Autora: Dra. Andrea Silvana Rosso
Trastornos
Trastornos de ansiedad (Parte 2) // Referencias bibliográficas panic disorder near the catechol-O-methyltransferase gene on chromosome 22. Biol Psychiatry, 2002. 51(7): p. 591-601. 75. Gorman, J.M., et al., Neuroanatomical hypothesis of panic disorder, revised. Am J Psychiatry, 2000. 157(4): p. 493-505. 76. Hoehn-Saric, R., et al., Somatic symptoms and physiologic responses in generalized anxiety disorder and panic disorder: an ambulatory monitor study. Arch Gen Psychiatry, 2004. 61(9): p. 913- 21. 77. Wilhelm, F.H., W. Trabert, and W.T. Roth, Physiologic instability in panic disorder and generalized anxiety disorder. Biol Psychiatry, 2001. 49(7): p. 596-605. 78. Abelson, J.L., et al., Persistent respiratory irregularity in patients with panic disorder. Biol Psychiatry, 2001. 49(7): p. 588-95. 79. Wilhelm, F.H., W. Trabert, and W.T. Roth, Characteristics of sighing in panic disorder. Biol Psychiatry, 2001. 49(7): p. 606-14. 80. Coryell, W., et al., Aberrant respiratory sensitivity to CO(2) as a trait of familial panic disorder. Biol Psychiatry, 2001. 49(7): p. 582- 7. 81. Sullivan, G.M., et al., The noradrenergic system in pathological anxiety: a focus on panic with relevance to generalized anxiety and phobias. Biol Psychiatry, 1999. 46(9): p. 1205-18. 82. Kim, Y.R., S.K. Min, and B.H. Yu, Differences in beta-adrenergic receptor sensitivity between women and men with panic disorder. Eur Neuropsychopharmacol, 2004. 14(6): p. 515-20. 83. Amital, D., et al., Anxiogenic effects of Sumatriptan in panic disorder: a double-blind, placebo-controlled study. Eur Neuropsychopharmacol, 2005. 15(3): p. 279-82. 84. Bremner, J.D., et al., SPECT (I-123)iomazenil measurement of the benzodiazepine receptor in panic disorder. Biol Psychiatry, 2000. 47(2): p. 96-106. 85. Kent, J.M., et al., Prediction of panic response to a respiratory stimulant by reduced orbitofrontal cerebral blood flow in panic disorder. Am J Psychiatry, 2005. 162(7): p. 1379-81. 86. Boshuisen, M.L., et al., rCBF differences between panic disorder patients and control subjects during anticipatory anxiety and rest. Biol Psychiatry, 2002. 52(2): p. 126-35. 87. Freud, S., Sobre la justificación de separar de la neurastenia un determinado síndrome en calidad de «neurosis de angustia», in Obras Completas, Amorrotu, Editor. 1995: Buenos Aires. p. 85-116. 88. Freud, S., Psicología de las masas y análisis del yo, in Obras Completas, Amorrotu, Editor. 1995: Buenos Aires. 89. Manassis, K., et al., Attachment in mothers with anxiety disorders and their children. J Am Acad Child Adolesc Psychiatry, 1994. 33(8): p. 1106-13. 90. Katerndahl, D.A., Symptom severity and perceptions in subjects with panic attacks. Arch Fam Med, 2000. 9(10): p. 1028-35. 91. Simon, N.M., et al., Changes in anxiety sensitivity with pharmacotherapy for panic disorder. J Psychiatr Res, 2004. 38(5): p. 491-5. 92. Liebowitz, M.R., Diagnostic Issues in Anxiety Disorders, in Review or Psychiatry, A.P. Press, Editor. 1992, Allan Tasman and Michelle Riba: Washington. p. 247-259. 93. Marquez, M., Psiquiatríaen medicina general: La ansiedad y sus trastornos. 2004, Buenos Aires: Editorial Polemos. 94. Segui, J., et al., Semiology and subtyping of panic disorders. Acta Psychiatr Scand, 1998. 97(4): p. 272-7. 95. de Graaf, R., et al., Risk factors for 12-month comorbidity of mood, anxiety, and substance use disorders: findings from the Netherlands Mental Health Survey and Incidence Study. Am J Psychiatry, 2002. 159(4): p. 620-9. 96. Goodwin, R.D., et al., Panic attack as a risk factor for severe psychopathology. Am J Psychiatry, 2004. 161(12): p. 2207-14. 97. MacKinnon, D.F., et al., Comorbid bipolar disorder and panic disorder in families with a high prevalence of bipolar disorder. Am J Psychiatry, 2002. 159(1): p. 30-5. 98. Ozkan, M. and A. Altindag, Comorbid personality disorders in subjects with panic disorder: do personality disorders increase clinical severity? Compr Psychiatry, 2005. 46(1): p. 20-6. 99. Simon, N.M. and D. Fischmann, The implications of medical and psychiatric comorbidity with panic disorder. J Clin Psychiatry, 2005. 66 Suppl 4: p. 8-15. 100. Lépine, J. and J. CHignon, Sémiologie des troubles anxieux et phobiques, in Encycl Méd Chir. Psychiatrie. 1994, Editions Scientifiques e médicales Elservier: Paris. p. 14. 101. Katschnig, H. and M. Amering, The long-term course of panic disorder and its predictors. J Clin Psychopharmacol, 1998. 18(6 Suppl 2): p. 6S-11S. 102. Barlow, D.H., et al., Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial. Jama, 2000. 283(19): p. 2529-36. 103. Pollack, M.H., The pharmacotherapy of panic disorder. J Clin Psychiatry, 2005. 66 Suppl 4: p. 23-7. 104. Bruce, S.E., et al., Are benzodiazepines still the medication of choice for patients with panic disorder with or without agoraphobia? Am J Psychiatry, 2003. 160(8): p. 1432-8. 105. Doyle, A. and M.H. Pollack, Long-term management of panic disorder. J Clin Psychiatry, 2004. 65 Suppl 5: p. 24-8. 106. Pollack, M.H., et al., Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder. J Psychopharmacol, 2003. 17(3): p. 276-82. 107. Barlow, J.H., et al., A review of self-management interventions for panic disorders, phobias and obsessive-compulsive disorders. Acta Psychiatr Scand, 2005. 111(4): p. 272-85. 108. Foa, E.B., M.E. Franklin, and J. Moser, Context in the clinic: how well do cognitive-behavioral therapies and medications work in combination? Biol Psychiatry, 2002. 52(10): p. 987-97. 109. Roy-Byrne, P.P., et al., A randomized effectiveness trial of cognitive-behavioral therapy and medication for primary care panic disorder. Arch Gen Psychiatry, 2005. 62(3): p. 290-8. 110. Kampman, M., et al., A randomized, double-blind, placebocontrolled study of the effects of adjunctive paroxetine in panic disorder patients unsuccessfully treated with cognitive-behavioral therapy alone. J Clin Psychiatry, 2002. 63(9): p. 772-7. 111. Toni, C., et al., Spontaneous treatment discontinuation in panic disorder patients treated with antidepressants. Acta Psychiatr Scand, 2004. 110(2): p. 130-7. 112. Mavissakalian, M.R. and S. Guo, Early detection of relapse in panic disorder. Acta Psychiatr Scand, 2004. 110(5): p. 393-9. 113. Akiskal, H.S., Toward a definition of generalized anxiety disorder as an anxious temperament type. Acta Psychiatr Scand Suppl, 1998. 393: p. 66-73. 114. Brown, T.A., D.H. Barlow, and M.R. Liebowitz, The empirical basis of generalized anxiety disorder. Am J Psychiatry, 1994. 151(9): Sciens Editorial TratadodeActualizaciónenPsiquiatría 27
CAPÍTULO XVI Trastornos de ansiedad (Parte 2) // Referencias bibliográficas p. 1272-80. 115. Hettema, J.M., C.A. Prescott, and K.S. Kendler, Genetic and environmental sources of covariation between generalized anxiety disorder and neuroticism. Am J Psychiatry, 2004. 161(9): p. 1581-7. 116. Ninan, P.T., Dissolving the burden of generalized anxiety disorder. J Clin Psychiatry, 2001. 62 Suppl 19: p. 5-10. 117. Keller, M.B., The long-term clinical course of generalized anxiety disorder. J Clin Psychiatry, 2002. 63 Suppl 8: p. 11-6. 118. Lieb, R., E. Becker, and C. Altamura, The epidemiology of generalized anxiety disorder in Europe. Eur Neuropsychopharmacol, 2005. 15(4): p. 445-52. 119. Kessler, R.C. and H.U. Wittchen, Patterns and correlates of generalized anxiety disorder in community samples. J Clin Psychiatry, 2002. 63 Suppl 8: p. 4-10. 120. Wittchen, H.U., et al., Generalized anxiety and depression in primary care: prevalence, recognition, and management. J Clin Psychiatry, 2002. 63 Suppl 8: p. 24-34. 121. Barlow, D.H. and J. Wincze, DSM-IV and beyond: what is generalized anxiety disorder? Acta Psychiatr Scand Suppl, 1998. 393: p. 23-9. 122. Rickels, K., R. Mangano, and A. Khan, A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. J Clin Psychopharmacol, 2004. 24(5): p. 488-96. 123. Andrews, G. and T. Slade, The classification of anxiety disorders in ICD-10 and DSM-IV: a concordance analysis. Psychopathology, 2002. 35(2-3): p. 100-6. 124. Ballenger, J.C., et al., Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry, 2001. 62 Suppl 11: p. 53- 8. 125. Grant, B.F., et al., The epidemiology of social anxiety disorder in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry, 2005. 66(11): p. 1351-61. 126. Lang, A.J. and M.B. Stein, Social phobia: prevalence and diagnostic threshold. J Clin Psychiatry, 2001. 62 Suppl 1: p. 5-10. 127. Nutt, D.J., Neurobiological mechanisms in generalized anxiety disorder. J Clin Psychiatry, 2001. 62 Suppl 11: p. 22-7; discussion 28. 128. Kendler, K.S., et al., The structure of the genetic and environmental risk factors for six major psychiatric disorders in women. Phobia, generalized anxiety disorder, panic disorder, bulimia, major depression, and alcoholism. Arch Gen Psychiatry, 1995. 52(5): p. 374-83. 129. Cascardo, E.R., Pablo, Trastorno de Ansiedad Generalizada. 2005, Buenos Aires: Editorial Polemos. 130. Gorman, J.M., Treatment of generalized anxiety disorder. J Clin Psychiatry, 2002. 63 Suppl 8: p. 17-23. 131. Goodman, W.K., Selecting pharmacotherapy for generalized anxiety disorder. J Clin Psychiatry, 2004. 65 Suppl 13: p. 8-13. 132. Lader, M.H., The nature and duration of treatment for GAD. Acta Psychiatr Scand Suppl, 1998. 393: p. 109-17. 133. Baldwin, D.S., et al., Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol, 2005. 19(6): p. 567-96. 134. Rickels, K., et al., Remission of generalized anxiety disorder: a review of the paroxetine clinical trials database. J Clin Psychiatry, 2006. 67(1): p. 41-7. 135. Dahl, A.A., et al., Sertraline in generalized anxiety disorder: efficacy in treating the psychic and somatic anxiety factors. Acta Psychiatr Scand, 2005. 111(6): p. 429-35. 136. Allgulander, C., D. Hackett, and E. Salinas, Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. Br J Psychiatry, 2001. 179: p. 15-22. 137. Davidson, J.R., Use of benzodiazepines in social anxiety disorder, generalized anxiety disorder, and posttraumatic stress disorder. J Clin Psychiatry, 2004. 65 Suppl 5: p. 29-33. 138. Pande, A.C., et al., Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry, 2003. 160(3): p. 533-40. 139. Llorca, P.M., et al., Efficacy and safety of hydroxyzine in the treatment of generalized anxiety disorder: a 3-month double-blind study. J Clin Psychiatry, 2002. 63(11): p. 1020-7. 140. Allgulander, C., Paroxetine in social anxiety disorder: a randomized placebo-controlled study. Acta Psychiatr Scand, 1999. 100(3): p. 193-8. 141. APA, Diagnostic and Statistical Manual of Mental Disorders, ed. e. revisada. 2000, Washington DC. 142. Westenberg, H. and L. M, Overview of Panic and Social Anxiety Disorders. Journal of Clinical Psychiatry, 2004. 65 Supplement 14: p. 22-26. 143. Fehm, L., et al., Size and burden of social phobia in Europe. Eur Neuropsychopharmacol, 2005. 15(4): p. 453-62. 144. Ballenger, J.C., et al., Consensus statement on social anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry, 1998. 59 Suppl 17: p. 54-60. 145. Sadock, B.J., V.A. Sadock, and H.I. Kaplan, Kaplan & Sadock's comprehensive textbook of psychiatry / editors, Benjamin J. Sadock, Virginia A. Sadock. 2000, Lippincott Williams & Wilkins: Philadelphia, PA. 146. Merikangas, K.R., Anxiety Disorders:Epidemiology, in Kaplan & Sadock's comprehensive textbook of psychiatry / editors, Benjamin J. Sadock, Virginia A. Sadock. 2005, Lippincott Williams & Wilkins: Philadelphia, PA. 147. Lecrubier, Y., Comorbidity in social anxiety disorder: impact on disease burden and management. J Clin Psychiatry, 1998. 59 Suppl 17: p. 33-8. 148. Kessler, R.C., The impairments caused by social phobia in the general population: implications for intervention. Acta Psychiatr Scand Suppl, 2003(417): p. 19-27. 149. Dewar, K.M. and A. Stravynski, The quest for biological correlates of social phobia: an interim assessment. Acta Psychiatr Scand, 2001. 103(4): p. 244-51. 150. Stein, D.J., et al., Predictors of response to pharmacotherapy in social anxiety disorder: an analysis of 3 placebo-controlled paroxetine trials. J Clin Psychiatry, 2002. 63(2): p. 152-5. 151. Marcin, M.S. and C.B. Nemeroff, The neurobiology of social anxiety disorder: the relevance of fear and anxiety. Acta Psychiatr Scand Suppl, 2003(417): p. 51-64. 152. Amaral, D.G., The primate amygdala and the neurobiology of 28 Dra. Andrea Silvana Rosso
